Dr. Aditya Pandey, MD
Claim this profileUniversity of Michigan
Studies Subarachnoid Hemorrhage
Studies Bleeding
2 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Aditya Pandey, MD is currently running
Intra-arterial Drug Therapy
for Cerebral Vasospasm
The primary objective of the study is to determine the optimal intra-arterial drug treatment regimen for arterial lumen restoration post cerebral vasospasm following aneurysmal subarachnoid hemorrhage. The secondary objective is to evaluate clinical outcome at 90 days post discharge following optimal intra-arterial drug treatment for cerebral vasospasm. We hypothesize that Intra-arterial (IA) infusion of a combination of multiple vasodilators is more efficacious than single agent treatment cerebral vasospasm therapy. All procedures done as a part of this study are standard hospital care procedures done to treat cerebral vasospasm and all drugs to be used are FDA approved.
Recruiting3 awards Phase 43 criteria
Deferoxamine
for Subarachnoid Hemorrhage
Aneurysmal subarachnoid hemorrhage (aSAH) has a high incidence of mortality and significant morbidity, with mortality exceeding 30% in the first two days.The initial injury is related to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with the release of iron. Iron has been shown to increase the incidence of cerebral edema, ischemia, and formation of hydrocephalus. Deferoxamine mesylate (DFO), a hydrophilic chelator, creates a stable complex with free iron thus preventing the formation of iron related free radicals. This trial will evaluate the safety and efficacy of clinical deferoxamine for the treatment of aSAH for patients that are admitted to the hospital at the University of Michigan or Peking University Health Science Center. Eligible participants will be enrolled and randomized to 1 of 2 doses of Deferoxamine or placebo (saline). Information regarding the patients will be collected and followed for up to 6 months post discharge.
Recruiting0 awards Phase 28 criteria
More about Aditya Pandey, MD
Clinical Trial Related8 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Aditya Pandey, MD has experience with
- Deferoxamine
- Placebo
- Nicardipine
- Nicardipine + Verapamil + Nitroglycerin
- Verapamil
Breakdown of trials Aditya Pandey, MD has run
Subarachnoid Hemorrhage
Brain Aneurysm
Cerebral Vasospasm
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Aditya Pandey, MD specialize in?
Aditya Pandey, MD focuses on Subarachnoid Hemorrhage and Bleeding. In particular, much of their work with Subarachnoid Hemorrhage has involved treating patients, or patients who are undergoing treatment.
Is Aditya Pandey, MD currently recruiting for clinical trials?
Yes, Aditya Pandey, MD is currently recruiting for 2 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Aditya Pandey, MD has studied deeply?
Yes, Aditya Pandey, MD has studied treatments such as Deferoxamine, Placebo, Nicardipine.
What is the best way to schedule an appointment with Aditya Pandey, MD?
Apply for one of the trials that Aditya Pandey, MD is conducting.
What is the office address of Aditya Pandey, MD?
The office of Aditya Pandey, MD is located at: University of Michigan, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.